NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
Taiwan Semiconductor
TSM
5
Super Micro Computer
SMCI
US Stock MarketDetailed Quotes
TEVA Teva Pharmaceutical Industries
- 15.690
- -0.310-1.94%
Close Mar 4 16:00 ET
- 15.730
- +0.040+0.25%
Post 20:01 ET
17.98BMarket Cap-10.82P/E (TTM)
16.060High15.270Low14.74MVolume15.750Open16.000Pre Close230.92MTurnover1.29%Turnover RatioLossP/E (Static)1.15BShares22.80052wk High3.35P/B17.90BFloat Cap12.51052wk Low--Dividend TTM1.14BShs Float68.007Historical High--Div YieldTTM4.94%Amplitude3.107Historical Low15.669Avg Price1Lot Size
Teva Pharmaceutical Industries Stock Forum
Can Teva's Injectable UZEDY Revolutionize Bipolar I Disorder Treatment? FDA Now Reviewing
$Greenwave Technology Solutions (GWAV.US)$
$Professional Diversity Network (IPDN.US)$
$Nuburu (BURU.US)$
$NewGenIvf (NIVF.US)$
$Pony AI (PONY.US)$
$Huize (HUIZ.US)$
$Teva Pharmaceutical Industries (TEVA.US)$
$Alvotech (ALVO.US)$
$NaaS Technology (NAAS.US)$
Can This New IBD Drug Outperform Current Treatments? Phase 2b Data Shows Remarkable 48% Remission Rate
FDA-Approved SELARSDI Launches: What Makes This Stelara® Alternative Different?
Major Eye Treatment Breakthrough: FDA Reviews New Affordable Eylea Alternative
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Catalyst Pharmaceuticals (CPRX) and its licensor SERB S.A. have reached a settlement agreement with Teva Pharmaceuticals regarding patent litigation over FIRDAPSE® (amifampridine). The litigation was initiated after Teva filed an Abbreviated New Drug Application seeking to market a generic version o...
No comment yet